Action GMAB GENMAB A/S
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Genmab A/S Nasdaq

Actions

GMAB

US3723032062

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/06/2024 		Varia. 5j. Varia. 1 janv.
25,67 USD -0,43% Graphique intraday de Genmab A/S -0,81% -19,38%
10/06 Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
04/06 GENMAB A/S : Truist Securities persiste à l'achat ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Transactions in Connection with Share Buy-back Program
Genmab A/S : has published its Articles of Association
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Genmab A/S - Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program
Transactions in Connection with Share Buy-back Program
Genmab A/S : has published its Articles of Association
Genmab A/S - Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Transactions in Connection with Share Buy-back Program
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Transactions in Connection with Share Buy-back Program
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action GMAB
  4. Action GMAB
  5. Actualités Genmab A/S
  6. Autres langues